ABSTRACT: Objective: To document variability among caregivers' priorities when considering medication to treat their Children's attention-deficit hyperactivity disorder (ADHD) and explore associations between these priorities and medication-related improvements. Methods: Caregivers of children, ages 4 to 14 years, diagnosed with ADHD were recruited from outpatient clinics and support groups across Maryland. A survey gathered data on caregiver-reported concerns when considering ADHD medication, demographic characteristics, and observed and desired improvements in their child's ADHD. A validated Best-Worst Scaling instrument assessed priorities among 16 concerns when considering ADHD medication. Latent class analysis identified subgroups with similar ADHD medication concerns. Differences in self-reported medication-related improvements were examined across subgroups. Results: The 184 participants (mean 5 42 yrs) were primarily the biological mother, 68% white and 25% black. Their children were mostly male (73%) and using medication (81%). Overall, the most important ADHD medication concerns were the child becoming a successful adult (p < 0.0001), school behavior improvements (p < 0.0001), and better grades (p < 0.0001). Others thinking badly of the child was a significantly less important concern (p < 0.0001). Three subgroups were identified: short-term outcomes-oriented group (39%), long-term outcomes-oriented group (37%), and side effects/safety-oriented group (27%). Relative to the other 2 groups, a smaller proportion of the side effects/safety-oriented group desired these improvements (p < 0.2618). Conclusion: Most caregivers prioritize short-and long-term outcomes when considering ADHD medication. However, those most concerned with long-or short-term outcomes tended to desire additional improvements in their child's ADHD.
The American Academy of Pediatrics clinical guidelines for attention-deficit hyperactivity disorder (ADHD) diagnosis and management emphasize the consideration of family preferences when developing a treatment plan. 1 Pediatric providers can face several challenges when attempting to implement these guidelines because the decision to use medication is a difficult process for many families. Most parents of Children diagnosed with ADHD often are hesitant to initiate medication, may consider medication unacceptable, 2, 3 and often face strong social influences impeding engagement in care. [4] [5] [6] [7] [8] [9] The perception that individuals in their community do not understand ADHD leads to mixed attitudes among families considering medication as part of an ADHD treatment plan. [10] [11] [12] [13] Those who feel supported by friends, family, and providers more willingly initiate medication.
14 These attitudes stem from family influence and social beliefs that stimulants are not safe, 6, 7 that children will be labeled and stigmatized, and that use will lead to future drug abuse. 6, 7, 15 Pediatric providers serve an important role in guiding parents through the informed consent process when deciding to use ADHD medication for their Children. Parents differ considerably in terms of their preferences and concerns with ADHD medication, and they must integrate competing priorities (e.g., "I want to limit any medication exposure to avoid side effects" vs "I want to seek optimal treatment that will help my child do well in school") to make a final decision about what is best for their children. When considering ADHD medication for their children, parents are weighing social influences to avoid ADHD medication, the likelihood of complete symptom resolution, the unknown long-term effects, 16, 17 and the potential for serious side effects. 18, 19 Despite several decades of research on ADHD treatment, the research literature is quite limited in guiding the practicing clinician on how to best identify these competing parental concerns in treatment decision making for their children. Not all parents weigh the benefits and risks of ADHD treatment similarly, 20 and so identifying subgroups with differing concerns could inform more patient-centered engagement in ADHD treatment. 21 The present study aims to document variation in caregivers' most important concerns when considering medication to treat their children's ADHD and to explore associations between these priorities and medicationrelated improvements. The specific focus was on 4 domains known to influence preferences: (1) short-term medication effects, (2) long-term medication effects, (3) social network support, and (4) stigma/isolation associated with having a child with ADHD. Here, the term caregiver is used to represent the parent or other legal guardian.
METHODS

Study Design and Procedures
A cross-sectional computer-facilitated survey elicited the relative importance of concerns that caregivers have when considering attention-deficit hyperactivity disorder (ADHD) medication for their children. Primary caregivers of children aged 4 to 14 years who had received an ADHD diagnosis were recruited between January 2013 and March 2015 from primary care and mental health pediatric outpatient clinics, parent support groups in public schools, and caregiver support organizations throughout Maryland. Participants provided written consent. Exclusions were made for those with cognitive impairments that would prevent them from completing the survey or who did not speak English. A brief telephone screen was conducted to determine eligibility and to confirm willingness to participate.
A research assistant scheduled a date and time to meet in person with eligible caregivers to review the consent form. To determine comprehension of what they would be asked to do if they joined the study, caregivers were asked to explain the study's purpose, what was expected of them, and what they could do if they no longer wished to participate in the study. Written consent was obtained only if individuals could answer the aforementioned questions.
The survey was completed in a private location either at the recruiting clinic or a public library. Before starting, the research staff went over the survey instructions. Caregivers completed the survey independently, but the research staff clarified any questions participants might have had. The survey took approximately 45 minutes to complete, and caregivers received a $25 gift card as compensation for their time. The University of Maryland, Baltimore, Institutional Review Board approved the study protocol.
Survey Instrument
The survey instrument comprised 3 sections: (1) sociodemographic characteristics of the caregiver and the child as well as the child's ADHD management; (2) Best-Worst Scaling (BWS) to elicit preferences for ADHD medication; and (3) caregiver-reported improvement in their child's ADHD.
Sociodemographic Information Caregivers self-reported demographic characteristics of themselves and their children and the children's ADHD treatment. Caregiver demographic information included their relation to the child, age, sex, race, education, annual household income, insurance type, number of individuals living in the same household, marital status, and occupation. Child demographic and ADHD care management information included the child's age, sex, years since diagnosed with ADHD, use of stimulant and other psychotropic medications, and receipt of therapy.
Best-Worst Scaling Best-Worst Scaling is a stated preference method with origins in marketing research but is increasingly used in health care research. 22, 23 We designed a BWS to elicit priorities when considering jointly competing concerns associated with an ADHD medication treatment decision for a child. The merits of BWS have been well documented 22, 23 and offer many advantages over traditional Likert-type response surveys. For 1, Likert scales elicit preferences for 1 attribute at a time. However, BWS presents the attributes simultaneously, forcing a choice (i.e., trade-offs) among potentially competing concerns. Also, because a choice is made in relation to other attributes, the item scores can be ranked in order of priority. Finally, BWS is more representative of real-life decision making where individuals often consider many factors when making a decision.
Using a previously validated instrument, 24, 25 we evaluated preferences for 16 attributes related to the short-term and long-term impact of ADHD medication on a child's well-being, societal views of using ADHD medication, and the influence of a social network. To reduce cognitive burden, we used a block design where each question (i.e., referred to as a choice-task profile) displayed 6 of the 16 attributes (Fig. 1 ). To ensure a balanced opportunity to select any 1 attribute, each of the 16 attributes appeared an equal number of times across all 16 choice-task profiles. For each choice-task profile, respondents selected 1 attribute that was most important and 1 attribute that was least important when considering ADHD medication.
Attention-Deficit Hyperactivity Disorder Improvement Several questions gathered self-reported observed and desired improvements in a child's ADHD in an openended free-text format. Caregivers indicated whether their children's ADHD improved, was unchanged, or worsened as a result of treatment. Using free-text format, caregivers noted any observed improvements or worsening of symptoms as well as additional changes they desired, if any.
Data Analysis
Caregiver and child demographics and self-reported observed and additional desired improvements in the child's ADHD were summarized using descriptive statistics. The research team coded free-text descriptions of observed and additional desired improvements into 3 categories: behavior (e.g., "better control of behavior, better attention, less distracted"), executive functioning (e.g., "better focused, more organized, completes tasks"), and school (e.g., "better grades at school, fewer problems at school"). The categories were not mutually exclusive because a caregiver could have observed or desired improvements in more than 1 domain.
Data were analyzed using Latent Gold Choice 5.1 Software to estimate attribute scores. The software uses a hybrid of Expectancy Maximization and NewtonRaphson algorithms. 26 Larger estimated scores reflected a stronger preference for the attribute. A positive value indicated that the attribute was an important influence on decision making, whereas a negative value indicated that the attribute was a less important influence on decision making. The scores can be ranked in order of importance (i.e., priority) to determine which is the most important relative to all other attributes.
To assess subgroup differences in preferences, we conducted a latent class analysis. Models were tested with 1 and up to 5 classes to identify the model that best fit the data. All models were scale adjusted for intrasubject variability in responses. Bayesian Information Criterion and Akaike Information Criterion fit statistics were used to select the best fitting model that generated theoretically interpretable classes. The Z-scores and associated p values were used to assess the significance of subgroup-specific importance scores (p , 0.05).
Bivariate x 2 statistics were used to compare differences in observed and desired outcomes as well as the ADHD treatment a child was currently receiving across latent groups. Analyses were conducted at the 5% significance level.
RESULTS
Demographic Characteristics
A total of 184 caregivers of children aged 4 to 14 years and in care for attention-deficit hyperactivity disorder (ADHD) completed the survey, with a 61% response rate. Caregivers were mainly white (68%), black (25%), or Hispanic (6.5%), aged 40 years and younger (48%), the child's biological mother (84%), married (64%), and completed at least some college education (74%). Most children were male (71%), had been diagnosed within the past 4 years (56%), and were taking at least 1 ADHD medication (81%) at the time of the survey. Children were, on average, 9.5 (62.5) years. Table 2 presents the rank order attribute scores for the aggregate sample. The most important concerns when deciding to use ADHD medication for their children were the children becoming a successful adult (m 5 1.83, SE 5 0.09), the medication helping the children's behavior in school (m 5 1.57, SE 5 0.08), and the medication helping the children's grades (m 5 1.48, SE 5 0.08). The influence of societal views and supportive network had large negative mean scores, suggesting these they were less important concerns in ADHD medication treatment decisions.
Attribute Importance
Preference Subgroups
A scale-adjusted 3-class solution was the best fitting model. The latent classes were as follows: short-term outcomes-oriented group (n 5 72; 39%), long-term outcomes-oriented group (n 5 68; 37%), and side effects/ safety-oriented group (n 5 44; 24%). Subgroup-specific attribute scores and 95% confidence intervals are displayed in Figure 2 . The short-term outcomes-oriented 22.09, SE 5 0.19) were least influential in the side effects/safety-oriented group. Many of the demographic characteristics were not statistically significantly different across preference subgroups (Table 1) . Caregivers in the long-term outcomes-oriented group were more likely to have public insurance compared with the other 2 groups (x 2 5 7.6, p 5 0.0224). Children of caregivers in the short-term outcomes-oriented group were more likely to be aged 10 years or older, whereas children of caregivers in the other 2 subgroups were more likely to be younger than 10 years (x 2 5 8.17, p 5 0.0168). A smaller proportion of side effects/safety-oriented caregivers (58%) reported using ADHD medication for their children compared with the short-(89%) or long-term (88%) outcomesoriented caregivers (x 2 5 19.9, p , 0.0001).
Observed Improvements and Additional Desired Improvements in Attention-Deficit Hyperactivity Disorder
Among the caregivers who used ADHD medication in their children 134 (89%) noticed an improvement in their children's ADHD, 13 (8%) believed as though their children's ADHD had remained the same, and 4 (3%) reported a worsening of their children's ADHD symptoms. Based on the free-text responses of observed improvements in the children's ADHD, 36% noted behavioral improvements (e.g., "a noticeable decrease in impulsivity and aggression"), 44% noted executive functioning improvements (e.g., "a distinct difference in ability to concentrate"), and 13% noted school improvements (e.g., "better school grades and focus").
When asked whether they desired additional improvements in their children's ADHD, nearly one-third of the caregivers who had noted improvements still reported seeking additional improvements. In particular, a large proportion of those who had seen either behavioral or executive functioning improvements desired further improvements in these areas. Thirty-four percent of 68 caregivers who observed a behavioral improvement in their children desired additional behavioral improvements. Among 81 caregivers who observed executive functioning improvements, 28% desired additional improvement in their children's executive functioning. Only 8% of 24 caregivers who observed improvement in school were still seeking additional improvement in school performance.
Caregiver report of additional desired changes in their children's ADHD differed significantly between those who used and those who did not use ADHD medication for their children. More than half (59%) of caregivers who had children using ADHD medication desired additional improvements in their children's ADHD, compared with 18% of caregivers whose children did not use Furthermore, a smaller proportion of the side effects/safetyoriented group (41%) reported that they would like to see additional improvements in their children's ADHD when compared with the long-term outcomes-oriented group (54%) and short-term outcomes-oriented group (56%); however, this did not reach statistical significance (x 2 5 2.7, p , 0.2618).
DISCUSSION
Although a number of studies have examined caregivers' concerns about attention-deficit hyperactivity disorder (ADHD) medication, this study elicited tradeoffs among different social and contextual issues influencing concerns about ADHD medication. The issues examined in this study are not necessarily specific to ADHD as caregivers of children with other developmental and behavioral pediatric conditions are often faced with decisions related to the safety of medications, stigma, and social support. 25 Stigma and social network support can be barriers to engagement in pediatric ADHD treatment. [10] [11] [12] The present study found that when assessing these factors in relation to other concerns, caregivers prioritized short-and longterm medication effects over stigma and social network influences. It also was notable that despite known sociodemographic differences in willingness to engage in ADHD treatment, 27 these characteristics were not significantly different across preference subgroups in the present study. This suggests that sociodemographic characteristics may not adequately distinguish the relative importance of contextual factors underlying treatment decisions. The findings offer recommendations for the management of ADHD.
A doctor addressing the caregivers' concerns was highly valued by this caregiver sample when considering ADHD medication for their children. A family-centered approach that considers caregivers' goals and priorities when developing care plans is vital, 11, 28 and the importance of the provider-patient relationship and shared decision making is documented in the literature. [28] [29] [30] Understanding caregivers' priorities for short-and longterm outcomes, stigma concerns, and ADHD medication side effects could guide initial ADHD treatment planning, ongoing monitoring, and managing social influences that can impede the delivery of evidence-based care.
Involving families in their children's care is among the American Academy of Pediatrics clinical recommendations, 1 and the present study suggests that managing expectations for treatment outcomes over the course of care may be important for engagement in care. Among those who observed improvements in their children's ADHD, a large portion was still hoping for additional improvements. Compared with caregivers who prioritized the long-and short-term treatment outcomes, fewer of those concerned primarily with the safety and side effects of ADHD medication reported seeking additional improvements in their children's ADHD. Understanding caregiver priorities for treatment outcomes may help clinicians to gauge perceptions of their children's ADHD improvement and caregiver engagement in treatment. Further research is warranted to determine whether caregivers who are seeking additional improvements over what already has been observed and those who are most concerned with the risks of ADHD medication are more likely to disengage from treatment, which is a commonly reported issue in pediatric mental health. 31, 32 Managing these expectations with caregivers may facilitate continued engagement in ADHD treatment.
The study is limited in several ways. One potential limitation is that all participants were recruited from 1 geographical area, and the results may not be generalizable to all caregivers of children with ADHD. In addition, despite efforts to recruit a diverse sample of participants by partnering with family support groups for low-income families, and pediatric clinics that serve underserved families, the majority of the sample had more than a high school diploma and high income, which may limit the generalizability of the results. Furthermore, all participants had a child with a clinician-assigned diagnosis of ADHD. It is possible that the sample of caregivers of a child already in care for ADHD had overcome some of the contextual and stigma-related barriers to engaging in care. This would explain the lower emphasis on these attributes relative to the outcome-oriented attributes. Caregivers' positive and negative experiences with medications the child or the caregivers' other children have taken previously could impact their views on and preferences for ADHD treatments and their propensity to start or continue medications. It is also possible that a child's comorbid conditions and academic history, including past grade retention, suspensions, and expulsions could influence ADHD treatment preferences, particularly school-related factors. Similarly, it is possible that caregivers' experiences with managing ADHD and interactions with the child's school influenced their responses. Although the scale-adjusted analysis accounted for potential response bias, it was not possible to control for the severity of a child's ADHD, which also may have affected caregivers' priorities for treatment. Future studies should examine the contextual issues, such as the influence of past experience with ADHD medications, past school suspensions, and impending school expulsions, that on caregivers' preferences compared with those who are not facing such contextual issues.
Despite the aforementioned limitations, there are several strengths worthy of mention. This study fills a gap in the existing literature on preference elicitation for ADHD treatment by simultaneously accounting for the social context influencing care management decisions. The priority ranking of preferences obtained from the Best-Worst Scaling (BWS) also is an important and novel contribution. Using a discrete choice experiment design, which like the BWS forces a choice among competing alternatives, Cunningham and colleagues identified 3 subgroups with different information needs for the management of child mental health problems. 33 By comparison, a recently published study using a Likert response survey to assess the information preferences of caregivers in deciding on treatment for their children's anxiety reported little variability in attribute importance that could guide clinical practice, i.e., nearly every attribute was rated as important. 34 In this case, attributes considered independently cannot be priority ranked because respondents were not asked to consider the importance of 1 attribute over the other when answering the question. In addition, the findings from the present study offer some preliminary evidence for the correlation between stated preferences and actual behaviors regarding treatment engagement. Ideally, this would have clinical practice relevance by guiding treatment plans toward the outcomes that are most important to caregivers. Finally, the preference elicitation methods used in the present study provide a unique opportunity to investigate the medical and social issues that often are competing alternatives in real-world health care decision making.
CONCLUSION
This study is important as the field is increasingly examining multiattribute facets of health and health care decision making. [35] [36] [37] These methods highlight the relative importance of competing alternatives in health care decision making, and thus are of value to a range of stakeholders, including policymakers, insurers, physicians, and patients, who must prioritize health care resources in an environment of limited funding. Furthermore, acknowledging early in the encounter the heterogeneity of preferences and how these may be correlated with treatment expectations could assist clinicians in developing family-centered treatment plans. The field of stated preference research in health-related areas has expanded tremendously in the past 10 years. The potential to link preferences for health care decisions with clinical data on impairment and severity is on the horizon as data linkages with electronic health records increase.
